Suzhou Zhongxi Bioinformatics Secures Pre-A++ Funding Round Led by Safeguard Puxin Healthcare Investment Fund

VCBeat has learned at the earliest opportunity that an innovative technology company in life sciences automationSuzhou PRCXI Bioinformatics Co., Ltd. (hereinafter referred to as “PRC Xi”)Once again favored by the capital market, it announced the completion of its Pre-A++ round of financing. This round was led bySaifu Puxin Investment FundExclusive investment. With this, PRC Xi has completed three rounds of financing within one year, with the previous two rounds receiving support from Wuzhong Financial Holdings, Rongyue Investment, and Qiming Venture Partners.

With the closing of this financing round, PRC Xi has officially entered a new phase of development. The funds raised will be primarily used to rapidly expand its R&D and production teams, accelerate the operation of new production facilities, achieve mass production of multiple products, and continuously enhance delivery capabilities to better meet the rapidly growing demands of industry customers.

PRC Xi was founded in 2014. Its core team has over a decade of experience in the field of life science automation. The company is committed to original R&D and dedicated to reducing costs and promoting accessibility, focusing on advancing the automation, systematization, and intelligence of life sciences. It provides reliable, efficient, and high-quality automated solutions for researchers both in China and abroad.

After more than a decade of original R&D, PRC Xi has mastered the core underlying technologies for automated liquid handling.Currently, the company's core pipetting product line encompasses 1- to 384-channel and independent 8-channel pipetting modules, flexibly addressing pipetting needs for 1- to 1536-well formats with a broad volume range from 25 nL to 10 mL.

In March 2024, PRC Xi launched an innovativeWide-Range Pipetting Module Technology，This innovation enables users to perform precise pipetting within a range of 0.5 to 1000 μL without replacing core components., significantly improving the efficiency and accuracy of the experiments.

PRC Xi boasts a diverse portfolio of standalone liquid handling instruments, designed to provide comprehensive pipetting solutions for laboratories of all types. While committed to technological innovation, PRC Xi also embraces the mission of accessibility, striving to deliver high-cost-performance products. The company believes that premium research tools should not be exclusive to well-funded laboratories; every researcher deserves access to a high-quality, high-efficiency research experience.

PRC Xi’s product portfolio is highly regarded not only for its applications in liquid handling within life science laboratories but also for the company’s robust in-house R&D capabilities and advanced manufacturing expertise in machining, sheet metal fabrication, mold making, and injection molding. By integrating cutting-edge technologies such as proprietary robotic arms, diverse modular components, machine vision, and AI-driven decision models, PRC Xi’s intelligent integrated systems have demonstrated exceptional performance in key fields including smart agriculture, organoid research, synthetic biology, and genomics, gradually becoming an accelerator for scientific innovation and industrial application advancement. Through continuous technological innovation, PRC Xi will comprehensively meet the complex demands of both research and industry, empowering the forefront of development in the life sciences sector.

Zhu Bin, Founder and CEO of PRC Xi“PRC Xi is not only a popularizer of life science automation but also a practitioner. It is our team’s commitment to this mission of popularization that continually drives us to optimize products, enhance quality, and reduce costs, making high-quality research tools more accessible. This enables more researchers to achieve greater scientific outcomes with lower investment. This is precisely the mission and vision that PRC Xi steadfastly upholds.”

Xu Hang, Managing Partner of Saifu Puxin Investment Fund“It is an inevitable trend for life science R&D to become automated and intelligent. However, constrained by high costs, many laboratories have yet to reap the significant benefits of precision and convenience offered by automated equipment. Leveraging its capabilities in exploring customer needs, product R&D, manufacturing, and application services, PRC Xi provides efficient solutions starting with liquid handling workstations. Its products, renowned for their high cost-performance ratio and flexible configurations, have gained widespread recognition. Sai Fu is honored to participate in this round of investment, aiming to help PRC Xi leverage its multifaceted leading advantages to become an industry leader in laboratory automation and promote the adoption of its solutions across various R&D units in the life sciences sector.”

SAIF Partners was established in 2001 as a private equity fund management firm specializing in investments in early-stage and growth-stage high-tech enterprises, ranking among China’s earliest large-scale equity investment fund management platforms. SAIF currently manages US dollar and RMB funds with a total asset under management (AUM) of nearly RMB 70 billion, having cumulatively invested in and managed nearly 400 companies, including more than 80 publicly listed companies both domestically and internationally. The SAIF Puxin Healthcare Investment Fund is SAIF’s fund dedicated to the broader healthcare sector; since its inception in 2017, it has invested in numerous leading enterprises across various sub-sectors, including YHLO Biotech (SH688575), Jiahua Medical Information Technology (SH688246), and Huaren Health (SZ301408).

SAIF Partners establishes long-term, close collaborative relationships with its portfolio companies, helping them expand their businesses, fully leverage synergies among enterprises, and introduce advanced management practices to maximize shareholder value.